Related Experiment Video
Updated: Dec 26, 2025
Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
Published on: March 30, 2019
Cyclin-dependent kinase inhibitors for the treatment of lung cancer
Angel Qin1, Haritha G Reddy1, Frank D Weinberg1
1Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan , Ann Arbor, MI, USA.
Introduction:
Cyclin-dependent kinases (CDKs) are critical regulators of cell cycle progression in both normal and malignant cells, functioning through complex molecular interactions. Deregulation of CDK-dependent pathways is commonly found in both non-small cell and small cell lung cancer, and these derangements suggest vulnerabilities that can be exploited for clinical benefit.
Areas Covered:
In this review, the authors present an overview of the biology of CDKs in normal and malignant cells, with a focus on lung cancer, followed by an assessment of preclinical work that has demonstrated the vital role of CDKs in lung cancer development and progression, and the activity of CDK inhibitors in a variety of lung cancer models. Finally, the experience with clinical trials of CDK inhibitors in lung cancer is discussed along with the current status of these agents in cancer therapy.
Expert Opinion:
Despite strong biological rationale and promising preclinical studies, the results of clinical trials of CDK inhibitors in lung cancer have thus far been disappointing. Further clinical development of CDK inhibitors in lung cancer will depend on the identification of predictive biomarkers and the design of combination regimens that take advantage of the unique molecular alterations that drive lung cancer growth and survival.
Insights
Cyclin-dependent kinases (CDKs) are crucial for cell cycle regulation. While CDK inhibitors show promise in preclinical lung cancer models, clinical trials have yielded disappointing results, necessitating biomarker identification and combination strategies.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- Cyclin-dependent kinases (CDKs) are key regulators of cell cycle progression.
- CDK pathway deregulation is common in lung cancers, indicating therapeutic vulnerabilities.
Purpose of the Study:
- To review CDK biology in normal and malignant cells, focusing on lung cancer.
- To assess preclinical data on CDK inhibitors in lung cancer models.
- To discuss clinical trial outcomes and the current status of CDK inhibitors in lung cancer therapy.
Main Methods:
- Literature review of CDK biology and function in lung cancer.
- Analysis of preclinical studies evaluating CDK inhibitors.
- Examination of clinical trial data for CDK inhibitors in lung cancer patients.
Main Results:
- Preclinical studies demonstrate the critical role of CDKs in lung cancer.
- CDK inhibitors have shown activity in various preclinical lung cancer models.
- Clinical trials of CDK inhibitors in lung cancer have thus far yielded disappointing outcomes.
Conclusions:
- Despite a strong biological rationale and promising preclinical data, clinical CDK inhibitor trials in lung cancer have underperformed.
- Future development requires identifying predictive biomarkers for patient selection.
- Combination regimens targeting specific lung cancer alterations are essential for progress.
More Related Videos
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
Related Concept Videos
02:34Inhibition of Cdk Activity
02:15M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
02:39Positive Regulator Molecules
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...